Q-omics provides the consensus-scored PSMC1P4 profile across patient tissues and cancer cell-line models. PSMC1P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PSMC1P4 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, PSMC1P4 RNA expression shows 6,488 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight KIRP, HNSC, and OV as cancer lineages where PSMC1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMC1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMC1P4 survival associations across molecular data types. PSMC1P4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMC1P4 RNA expression–survival associations across cancer types. High PSMC1P4 expression shows unfavorable associations in KIRP, MESO, COAD, KIRC, KICH and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PSMC1P4 RNA expression.
This table summarizes PSMC1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PSMC1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMC1P4 shows higher tumor expression in HNSC, LUSC, CHOL, STAD and LUAD. The HNSC box plot shows higher PSMC1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.029, t-test p = .010).
This table shows molecular features associated with PSMC1P4 in patient tissues and cancer cell lines. In patient samples, PSMC1P4 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
